Collaboration NVI and Sanofi Pasteur

The Netherlands Vaccine Institute and Sanofi Pasteur collaborate on the development of a protein-based vaccine for a broader prevention of pneumococcal disease. A clinical trial for safety and immunogenicity started this week in Switzerland.

AmpVacs a broadly protective synthetic influenza A vaccine

Sanquin Blood Supply Foundation, the Netherlands Cancer Institute, and the Netherlands Vaccine Institute announce today the launch of their joint AmpVacs project aiming at the development of a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats.